PET/CT: Molekulare Diagnostik und Theragnostik für die Radionuklidtherapie

Thorsten Derlin; Frank M. Bengel

doi:10.1055/s-0042-117979

Pneumologie, Inhaltsverzeichnis

Pneumologie 2017; 71(01): 48-62
DOI: 10.1055/s-0042-117979

Fort- und Weiterbildung

PET/CT: Molekulare Diagnostik und Theragnostik für die Radionuklidtherapie

PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy

Thorsten Derlin

,

Frank M. Bengel

Abstract

Die kombinierte Positronenemissions- und Computertomografie (PET/CT) ist unverzichtbarer Bestandteil vieler diagnostischer Algorithmen in der Pneumologie geworden. Mit ihr können exakte anatomische und molekulare Informationen erfasst werden, sodass Erkrankungen umfassend charakterisiert werden können. Mit ¹⁸F-Fluorodeoxyglukose (FDG) steht ein universell einsetzbarer Radiotracer zur Darstellung maligner und entzündlicher Prozesse zur Verfügung.

Volltext

Referenzen

Literatur
1 Boellaard R, Delgado-Bolton R, Oyen WJ. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354
2 Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009; 50: 11-20
3 Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Tumoren. Biochem Z 1924; 152: 319-344
4 de Geus-Oei LF, van Krieken JH, Aliredjo RP. et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007; 55: 79-87
5 Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med 2006; 47: 451-469
6 Midthun DE, Swensen SJ, Jett JR. Approach to the solitary pulmonary nodule. Mayo Clin Proc 1993; 68: 378-385
7 Winer-Muram H. The solitary pulmonary nodule. Radiology 2006; 239: 34-49
8 Murthy SC, Rice TW. The solitary pulmonary nodule: a primer on differential diagnosis. Semin Thorac Cardiovasc Surg 2002; 14: 239-249
9 National Lung Screening Trial Research Team. Aberle DR. Adams AM. et al. educed lung-cancer mortality with low-dose computed tomographic screening. Engl J Med 2011; 365: 395-409
10 McWilliams A, Tammemagi MC, Mayo JR. et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013; 369: 910-919
11 Cronin P, Dwamena BA, Kelly AM. et al. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008; 246: 772-782
12 Goeckenjan G, Sitter H, Thomas M. et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society – abridged version]. Pneumologie 2011; 65: e51-e75
13 Horeweg N, van Rosmalen J, Heuvelmans MA. et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 2014; 15: 1332-1341
14 Gould MK, Maclean CC, Kuschner WG. et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924
15 Apostolova I, Wiemker R, Paulus T. et al. Combined correction of recovery effect and motion blur for SUV quantification of solitary pulmonary nodules in FDG PET/CT. Eur Radiol 2010; 20: 1868-1877
16 Deppen SA. Blume JD. Kensinger CD. et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 2014; 312: 1227-1236
17 Schmidt-Hansen M, Baldwin DR, Hasler E. et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev 2014; 11: CD009519
18 Gould MK, Kuschner WG, Rydzak CE. et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-892
19 Birim O, Kappetein AP, Stijnen T. et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005; 79: 375-382
20 Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA. et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 2005; 23: 8348-8356
21 de Langen AJ, Raijmakers P, Riphagen I. et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006; 29: 26-29
22 MacManus MP, Hicks RJ, Matthews JP. et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287-293
23 Erasmus JJ, Patz Jr EF, McAdams HP. et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR 1997; 168: 1357-1360
24 Bury T, Barreto A, Daenen F. et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-1247
25 Pieterman RM, van Putten JW, Meuzelaar JJ. et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254-261
26 van Tinteren H, Hoekstra OS, Smit EF. et al. Effectiveness of positron emission tomography in preoperative assessment of patients with suspected non-small cell lung cancer: The PLUS multicentre randomized trial. Lancet 2002; 359: 1388-1393
27 Fischer B, Lassen U, Mortensen J. et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009; 361: 32-39
28 Im HJ, Pak K, Cheon GJ. et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging 2015; 42: 241-251
29 Bradley J, Thorstad WL, Mutic S. et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59: 78-86
30 Nestle U, Kremp S, Schaefer-Schuler A. et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005; 46: 1342-1348
31 Braun JJ, Kessler R, Constantinesco A. et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-1543
32 Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J. et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53: 1543-1549
33 Keijsers RG, Verzijlbergen EJ, van den Bosch JM. et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 123-129
34 Valeyre D, Prasse A, Nunes H. et al. Sarcoidosis. Lancet 2014; 383: 1155-1167
35 Blankstein R, Osborne M, Naya M. et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336
36 Osborne MT, Hulten EA, Singh A. et al. Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014; 21: 166-174
37 Ohira H, Birnie DH, Pena E. et al. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2016; 43: 259-269
38 Ohira H, Tsujino I, Ishimaru S. et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933-941
39 Lococo F, Perotti G, Cardillo G. et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clin Nucl Med 2015; 40: e183-189
40 Venkitaraman B, Karunanithi S, Kumar A. et al. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 2014; 41: 856-864
41 Baum RP, Kulkarni HR, Schuchardt C. et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med 2016; 57: 1006-1013
42 Lapa C, Lückerath K, Rudelius M. et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer – initial experience. Oncotarget 2016; 7: 9288-9295